Article

Ciliary neurotrophic factor may be therapeutic for RP

Ciliary neurotrophic factor (CNTF), a member of the interleukin family of proteins, seems to be safe and promising for treating patients with retinitis pigmentosa (RP) when delivered into the eye via sequestered live cell intraocular implants, said Paul Sieving, MD, PhD, director of the National Eye Institute, Bethesda, MD.

Ciliary neurotrophic factor (CNTF), a member of the interleukin family of proteins, seems to be safe and promising for treating patients with retinitis pigmentosa (RP) when delivered into the eye via sequestered live cell intraocular implants, said Paul Sieving, MD, PhD, director of the National Eye Institute, Bethesda, MD.

In a phase I non-randomized, open-label clinical trial, CNTF, which has been shown in animal models to rescue photoreceptors from death, was introduced in one eye of 10 patients through a small incision in the sclera in a 6- × 1-mm implant. CNTF is then released into the vitreous. Five patients received low-dose implants and five received higher-dose implants. The capsules remained implanted for 6 months before they were explanted. Preoperatively, three patients had little visual acuity, and seven eyes had measurable visual acuity.

"The outcome of the safety study was good and provided the basis for going forward with other studies; however, more specifically, we found a remarkable change in visual function exceeding 10 letters in three patients," Dr. Sieving said. "These patients with RP with macular atrophy began to recover visual function halfway through the study. There was no change in the untreated fellow eye. The improvement in visual acuity was sustained 6 months after the implants were removed."

He also pointed out that this result led to the idea to use CNTF for geography atrophy in age-related macular degeneration.

The question that must be addressed regarding these patients is how CNTF actually improves visual function. CNTF may be able to rescue dormant-but-not-dead photoreceptors, Dr. Sieving said.

"It is possible that the photoreceptors may remain viable even though they are not functioning," he said, adding that this is a concept that will undergo evaluation in the phase II/III study.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.